LMATMEDIUM SIGNALFINANCIAL10-K

LeMaitre Vascular delivered strong operational performance with 31% net income growth, but interest expense spiked dramatically from $205K to $5.2M, indicating significant new debt or financing changes.

The massive 2,428% increase in interest expense suggests LMAT took on substantial new debt during fiscal 2025, which investors should investigate further to understand the purpose and terms. Despite this financing change, the company demonstrated strong underlying business performance with meaningful improvements across revenue, profitability, and cash generation.

Comparing 2026-02-26 vs 2025-02-28View on EDGAR →
FINANCIAL ANALYSIS

LMAT showed robust financial performance with net income growing 31% to $57.7M and operating cash flow surging 84% to $81.3M, indicating strong business momentum. However, the dramatic spike in interest expense from $205K to $5.2M signals significant new borrowing that needs explanation. The company expanded operations with sales force growth from 152 to 160 representatives and higher inventory levels, while maintaining healthy balance sheet growth across assets and equity, suggesting the business is scaling effectively despite the new debt burden.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
+2428.8%
$205K→$5.2M

Interest expense surged 2428.8% — significant debt increase or rising rates materially impacting earnings.

Operating Cash Flow
Cash Flow
+84.1%
$44.1M→$81.3M

Operating cash flow surged 84.1% — exceptional cash generation, highest quality earnings signal.

Net Income
P&L
+31.1%
$44.0M→$57.7M

Net income grew 31.1% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+30%
$52.3M→$67.9M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Inventory
Balance Sheet
+28.8%
$15.2M→$19.6M

Inventory built 28.8% — monitor whether demand supports this build or if write-downs may follow.

Capital Expenditure
Cash Flow
+25%
$2.3M→$2.8M

Capex increased 25% — ongoing investment in capacity or infrastructure for future growth.

Current Liabilities
Balance Sheet
+18.7%
$30.6M→$36.3M

Current liabilities rose 18.7% — increased short-term obligations, watch current ratio.

Gross Profit
P&L
+18.3%
$150.9M→$178.5M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Stockholders Equity
Balance Sheet
+16.7%
$337.3M→$393.5M

Equity base grew 16.7% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Current Assets
Balance Sheet
+16.4%
$402.2M→$468.2M

Current assets grew 16.4% — improving short-term liquidity or inventory/receivables build.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-02-28
ADDED
As of February 19, 2026, the registrant had 22,778,363 shares of common stock, par value $0.01 per share, outstanding.
LeMaitre, AlboGraft, AnastoClip, AnastoClip GC, Artegraft, CardioCel, Eze-Sit, Glow N Tell, LifeSpan, PhasTipp, Pruitt, Pruitt F3, RestoreFlow, Syntel, TufTex, VascuCel, VascuTape, and XenoSure are U.S.
registered trademarks of LeMaitre Vascular or one of its subsidiaries, and AndraValvulotome, Flexcel, and Omniflow are trademarks of LeMaitre Vascular.
B usiness Overview We are a global provider of medical devices and human tissue cryopreservation services largely used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease.
As of December 31, 2025, our sales force comprised 160 sales representatives and export managers in North America, Europe, and Asia Pacific.
+7 more — sign up free →
REMOVED
As of February 24, 2025, the registrant had 22,558,631 shares of common stock, par value $0.01 per share, outstanding.
Business Overview LeMaitre Vascular is a global provider of medical devices and human tissue cryopreservation services largely used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease.
As of December 31, 2024, our sales force comprised 152 sales representatives in North America, Europe, the United Kingdom, or UK, and Asia Pacific, including four export managers.
We estimate that in 2024, over 95% of our net sales were from devices used in open surgical procedures.
We believe that the relative lack of focus on these segments by larger competitors, as well as the differentiated features and consistent availability and quality of our products, enable higher selling prices and market share gains.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →